A phase 1 study of triple-targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF-mutated cancers

By sjmartinez • April 30, 2024

Algazi AP, Moon J, Lao CD, Chmielowski B, Kendra KL, Lewis KD, Gonzalez R, Kim K, Godwin JE, Curti BD, Latkovic-Taber M, Lomeli SH, Gufford BT, Scumpia PO, Lo RS, Othus M, Ribas A. A phase 1 study of triple-targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF-mutated cancers. Cancer. 2024 May 15;130(10):1784-1796. doi: 10.1002/cncr.35200. Epub 2024 Jan 23. PMID: 38261444.

Tags: Dermatology, Hematology/Oncology, melanoma, mitogen‐activated protein kinase, nonsmall cell lung cancer, papillary thyroid carcinoma, phosphatidylinositol‐3' kinases, proto‐oncogene proteins B‐RAF, Publications

Contact Dermatitis in the United States: A Population-Based Study on Patient Visit Characteristics and Treatment Prescription Patterns

Hao A, Yu RP, Kikuchi R, Sadrolashrafi K, Guo L, Yamamoto RK, Tolson H, Yee D, Bilimoria S, Pourali SP, Adler BL, Armstrong AW. Contact[...]

Radiation therapy for a case of poikilodermatous plaques in an otherwise healthy young man: A case report

Biba U, Poppens MJ, Collier EK, Cheng K. Radiation therapy for a case of poikilodermatous plaques in an otherwise healthy young man: A case report.[...]

Editorial: Developing next-generation therapeutics to defeat mutation-driven cancer

Chow F, Lamoureux F, Moriceau G. Editorial: Developing next-generation therapeutics to defeat mutation-driven cancer. Front Immunol. 2024 Sep 26;15:1487952. doi: 10.3389/fimmu.2024.1487952. PMID: 39391312; PMCID: PMC11464455.